H uman African trypanosomiasis (HAT or sleeping sickness), caused by Trypanosoma brucei gambiense, is a slowly progressing fatal infectious disease that affects an estimated 100,000 persons in Central Africa each year. In the meningoencephalitic or second stage, melarsoprol, an arsenic derivative, and efl ornithine are the only effective drug treatments available (1). High relapse rates for patients treated with melarsoprol were documented in Uganda (2, 3) and in M'banza Congo in Angola (4) . We investigated recent reports about very high relapse rates from the province of North Equator, in the Democratic Republic of Congo (DRC), where the largest HAT epidemic in recent history occurred (5).
The Study
We reviewed the records of all patients who received HAT treatment in the period January 1, 2001-December 31, 2003, in the 23 treatment centers operating in North Equator Province. We included only those case-patients who had received complete treatment with melarsoprol, obtained from Sanofi Aventis (Paris, France) under the World Health Organization donation program with 1 of the following regimens: 3 series of 3 injections (3.4 mg/kg) at 7-day intervals for patients with a cerebrospinal fl uid (CSF) leukocyte count >20 leukocytes/mm 3 , or 2 series of 3 injections (3.4 mg/kg) at 7-day intervals for patients with CSF leukocyte counts of 5-20 leukocytes/mm 3 . Patients were asked to return for a routine follow-up visit to the HAT treatment center at 6, 12, 18, and 24 months after treatment or any time they felt unwell between visits.
Age, sex, disease stage, and results of parasitologic tests of the patients who experienced a relapse were recorded during the chart review. HAT relapse was defi ned as follows: trypanosomes found in body fl uids at any follow-up assessment or a CSF leukocyte count >20/mm 3 and twice as high as the count at the previous follow-up visit. This case defi nition for relapse is used by the national program and in clinical trials (6) . Patients who did not show up for suggested follow-up visits were not visited at home.
The relapse rate was calculated as the number of patients with HAT who experienced a relapse, divided by all patients who received full melarsoprol treatment during the study period. The study included 4,925 patients with second-stage parasitologically confi rmed HAT; all were treatment-naïve for HAT, and none had been referred by another center. Relapse after melarsoprol treatment was noted for 959 (19.5%) patients. Table 1 Table 2 shows characteristics of the patients with a relapse of HAT after melarsoprol treatment. Lumbar puncture was performed for 92% of patients at 6 months. This proportion dropped to 73% after 2 years, according to the annual reports for 2001-2005. Only 4.8% of patients with fi rst-stage illness experienced a relapse; direct evidence of the parasite was found in 27% of these case-patients.
Conclusions
These data show that high failure rates with melarsoprol are no longer limited to Kasai Province in DRC. The HAT focus of the Equateur Nord Province does not border that in the Kasai Province, and given the limited contact between both provinces, resistant strains likely did not spread from Kasai to Equateur Nord Province.
The reported failure rate is certainly underestimated because some of the patients who did not return for follow-up visits probably died at home or sought treatment elsewhere. We cannot exclude the possibility that some retreated patients had been reinfected. However, the trend in observed incidence rates in Equateur Nord Province had been declining since 2004, and, regardless, the incidence was too low to contribute substantially to the observed 19.5% failure rate. The program used only basic parasitologic confi rmation tests and none of the more sensitive concentration techniques, such as capillary tube centrifugation, quantitative buffy coat test, or the miniature anionexchange column for trypanosomiasis during the study period, which explains the low proportion of relapses that were parasitologically confi rmed.
Melarsoprol was used on a massive and unprecedented scale in Equateur Nord Province from 1996 through 2005, when 38,945 new patients received treatment with melarsoprol (annual reports of national program 2000 and 2005), so drug pressure (i.e., the use of a certain antimicrobioal agent potentially selecting out resistant strains) was certainly present in the region. Similarly high failure rates with melarsoprol in the Kasai Province led the national control program to introduce efl ornithine as a fi rst-line treatment there in 2006. The cause of these high relapse rates remains unclear because until now melarsoprol resistance could not be demonstrated in parasites in vitro or in animal models (5) . The program used a shorter melarsoprol treatment regimen than that used by other countries, where 3 series of 4 injections are used. This difference is unlikely to be an explanation for the high relapse rates found, however, as in other provinces of DRC, relapse rates with the same regimen remained considerably lower (e.g., a 1.4% reported relapse rate for Bandundu Province, according to the 2006 Annual Report of the national control program).
Given this high failure rate, a switch to the safer eflornithine regimen is the most obvious solution. However, this drug is more complex to administer: patients receiving it require intravenous fl uids and a high standard of nursing care. Efl ornithine offers the additional advantage of lesser toxicity, which might enhance the acceptability of HAT treatment. A cost-effectiveness analysis showed that efl ornithine is the more cost-effective option whenever relapse rates with melarsoprol treatment exceed 15% (7). Legitimate concerns have been raised regarding the use of this drug in monotherapy as fi rst-line treatment because there are no alternatives if resistance to it emerges. A clinical trial on the use of the combination DFMO (alphadifl uoromethylornithine)-nifurtimox is in progress (8) . Our data show the urgent need for novel drugs for stage-2 HAT. Public-private partnerships such as the Drugs for Neglected Diseases Initiative and others are currently investing in development of such drugs, but a new drug will not likely be available within the next decade. Therefore, rapidly controlling new outbreaks is essential to prevent large epidemics. These outbreaks may be more diffi cult to control if efl ornithine resistance emerges. 
